EHealth: Individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2276-2285

  Pedersen, Natalia ^a   Thielsen, Peter ^a   Martinsen, Lars ^b   Bennedsen, Mette ^c   Haaber, Anne ^a   Langholz, Ebbe ^a   Végh, Zsuzsanna ^a   Duricova, Dana ^d   Jess, Tine ^e   Bell, Sally ^f   Burisch, Johan ^a   Munkholm, Pia ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NYKØBING FALSTER HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d CHARLES UNIVERSITY   (Czech Republic)

^e STATENS SERUM INSTITUT   (Denmark)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Inflammatory bowel disease; Mesalazine; Multimatrix system; Ulcerative colitis; Web based management

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIANAL ABSCESS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; SELF CARE; SHORT FORM 12; TELEHEALTH; TREATMENT DURATION; ULCERATIVE COLITIS; VERTIGO; VISUAL ANALOG SCALE; ATTITUDE TO HEALTH; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; INTERNET; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT EDUCATION; PROGNOSIS; PSYCHOLOGY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TEACHING; TELEMEDICINE; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COMPUTER-ASSISTED INSTRUCTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INDIVIDUALIZED MEDICINE; INTERNET; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; SELF CARE; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; YOUNG ADULT;

EID: 84925819829     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000199     Document Type: Article

References (59)

1. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999;46:400-415.
2. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36-46.
3. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266.
4. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;CD004115.
5. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960-965.
6. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672-678.
7. Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:2070-2077.
8. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601-616.
9. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56:3463-3470.
10. Munkholm P, Michetti P, Probert CS, et al. Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. Eur J Gastroenterol Hepatol. 2010;22:912-916.
11. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
12. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut. 2010;59:1652-1661.
13. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
14. Baars JE, Zelinkova Z, Mensink PB, et al. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study. Aliment Pharmacol Ther. 2009;30:864-872.
15. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13: 1244-1249.
16. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417-1426.
17. Gifford AE, Berg AH, Lahiff C, et al. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013;108:249-255.
18. Lakatos PL, Czegledi Z, David G, et al. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis. 2010;4:283-290.
19. Lopez San RA, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97:249-257.
20. Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17:1874-1881.
21. Long MD, Kappelman MD, Martin CF, et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis. 2012;18:2099-2106.
22. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98: 1535-1544.
23. Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol. 2002;97:1853.
24. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247-257.
25. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, highconcentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75.
26. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893-902.
27. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8.
28. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once-or twicedaily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5:95-102.
29. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008;27:1094-1102.
30. Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008;2:299-314.
31. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
32. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62.
33. Pedersen N, Elkjaer M, Duricova D, et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ther. 2012;36:840-849.
34. Elkjaer M, Burisch J, Avnstrom S, et al. Development of a web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol. 2010;22:695-704.
35. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
36. Jowett SL, Seal CJ, Phillips E, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38: 164-171.
37. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
38. Elkjaer M, Burisch J, Voxen H, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:323-330.
39. Horne R, Chapman SC, Parham R, et al. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633.
40. Hunot VM, Horne R, Leese MN, et al. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9:91-99.
41. Ohm R, Aaronson LS. Symptom perception and adherence to asthma controller medications. J Nurs Scholarsh. 2006;38:292-297.
42. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578.
43. Burisch J, Weimers P, Pedersen N. Health related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease-an ECCO-EpiCom study. J Crohns Colitis. 2014;8:1030-1042.
44. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. 2014;61:B4778.
45. Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1167-1170.
46. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-769.
47. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(suppl 1):S2-S25.
48. Iacucci M, de SS, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010;24:127-133.
49. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18:1026-1033.
50. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
51. De VM, Dewit O, D'Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562.
52. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858.
53. Schoepfer AM, Vavricka S, Zahnd-Straumann N, et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis. 2012;6:412-418.
54. Solomon D, Yarlas A, Hodgkins P, et al. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther. 2012;35:1386-1396.
55. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
56. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.
57. Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10:43.
58. Inokuchi T, Kato J, Hiraoka S, et al. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol. 2014;20:509-517.
59. Delvincourt M, Lopez A, Pillet S, et al. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:712-720.